Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2007-03-13
2007-03-13
Huff, Sheel J. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S388100, C530S388230, C530S391100, C530S391300, C530S391700, C424S133100, C424S135100, C424S141100, C424S145100, C435S069600, C435S235100, C435S328000
Reexamination Certificate
active
10151882
ABSTRACT:
The present invention relates to antibodies and related molecules that immunospecifically bind to Tumor Necrosis Factor Delta (TNF-delta; APRIL). The present invention also relates to methods and compositions for detecting, diagnosing, prognosing, treating, preventing, or ameliorating a disease or disorder associated with aberrant APRIL or APRIL receptor expression or aberrant function of APRIL or APRIL receptor, comprising antibodies or fragments or variants thereof, or related molecules, that immunospecifically bind to APRIL. In particular, the present invention further relates to methods and compositions for detecting, diagnosing, prognosing, preventing, treating or ameliorating autoimmune diseases or disorder, such as systemic lupus erythematosus Rheumatoid arthritis, and Sjögren's syndrome, or cancers of the immune system, particularly B cell cancers such as non-Hodgkin's lymphoma and multiple myeloma, comprising administering to an animal, preferably a human, an effective amount of one or more antibodies or fragments or variants thereof, or related molecules, that immunospecifically bind to APRIL.
REFERENCES:
patent: 5487984 (1996-01-01), Allet et al.
patent: 5916771 (1999-06-01), Hori et al.
patent: 5925548 (1999-07-01), Beutler et al.
patent: 6171787 (2001-01-01), Wiley
patent: 6297022 (2001-10-01), McDonnell et al.
patent: 6297367 (2001-10-01), Tribouley
patent: 6440694 (2002-08-01), Bienkowski et al.
patent: 6506882 (2003-01-01), Yu et al.
patent: 6509170 (2003-01-01), Yu et al.
patent: 6541224 (2003-04-01), Yu et al.
patent: 6635482 (2003-10-01), Yu et al.
patent: 2002/0055474 (2002-05-01), Busfield
patent: 2002/0072089 (2002-06-01), Holtzman et al.
patent: 2003/0059937 (2003-03-01), Ruben et al.
patent: 2003/0100074 (2003-05-01), Yu et al.
patent: 2003/0166864 (2003-09-01), Yu et al.
patent: 2003/0175208 (2003-09-01), Yu et al.
patent: 2003/0198640 (2003-10-01), Yu et al.
patent: 2003/0223996 (2003-12-01), Ruben et al.
patent: 0 911 633 (1999-04-01), None
patent: 0 919 620 (1999-08-01), None
patent: WO93/16178 (1993-08-01), None
patent: WO97/33902 (1997-09-01), None
patent: WO-98/56906 (1998-12-01), None
patent: WO99/00518 (1999-01-01), None
patent: WO99/11791 (1999-03-01), None
patent: WO99/12965 (1999-03-01), None
patent: WO99/28462 (1999-06-01), None
patent: WO99/33980 (1999-07-01), None
patent: WO99/35170 (1999-07-01), None
patent: WO99/50416 (1999-10-01), None
patent: WO99/54460 (1999-10-01), None
patent: WO99/55858 (1999-11-01), None
patent: WO00/26244 (2000-05-01), None
patent: WO00/32776 (2000-06-01), None
patent: WO00/37640 (2000-06-01), None
patent: WO00/50597 (2000-08-01), None
patent: WO00/55320 (2000-09-01), None
patent: WO 200063699 (2000-10-01), None
patent: WO00/68378 (2000-11-01), None
patent: WO00/77256 (2000-12-01), None
patent: WO01/24811 (2001-04-01), None
patent: WO01/25256 (2001-04-01), None
patent: WO01/58949 (2001-08-01), None
patent: WO01/60397 (2001-08-01), None
patent: WO01/077291 (2001-10-01), None
patent: WO01/81417 (2001-11-01), None
patent: WO01/87979 (2001-11-01), None
patent: WO02/038766 (2002-05-01), None
patent: WO02/064829 (2002-08-01), None
patent: WO02/094852 (2002-11-01), None
patent: WO03/014294 (2003-02-01), None
patent: WO03/022877 (2003-03-01), None
patent: WO03/035846 (2003-05-01), None
patent: WO03/040307 (2003-05-01), None
Rudikoff et al. Proc. Natl. Acad. Sci. USA, 79:1979-1983, 1982.
Coleman P. M. Research in Immunology, 145:33-36, 1994.
Brown et al. The Journal of Immunology, 156:3285-3291, 1996.
Gruss et al., “Tumor Necrosis Factor Ligand Superfamily: Involvement in the Pathology of Malignant Lymphomas,” Blood 85(12):3378-3404, 1995.
Hahne et al., “APRIL, a New Ligand of the Tumor Necrosis Factor Family, Stimulates Tumor Cell Growth,” Journal of Experimental Medicine 188(6):1185-1190, 1998.
Kelly et al., “APRIL/TRDL-1, a tumor necrosis factor-like ligand, stimulates cell death,” Cancer Research 60(4):1021-1027, 2000.
Marsters et al., “Interaction of the TNF homologues BlyS and APRIL with the TNF receptor homologues BCMA and TACI,” Current Biology 10(13):785-788, 2000.
Wu et al., “Tumor Necrosis Factor (TNF) Receptor Superfamily Member TACI is a High Affinity Receptor for TNF Family Members APRIL and BLyS,” Journal of Biological Chemistry 275(45):35478-35485, 2000.
Rennert et al., “A Soluble Form of B Cell Maturation Antigen, a Receptor for the Tumor Necrosis Factor Family Member APRIL, Inhibits Tumor Cell Growth,” Journal of Experimental Medicine 192(11):1677-1683, 2000.
Ware, C., “APRIL and BAFF Connect Autoimmunity and Cancer,” Journal of Experimental Medicine 192(11):F35-F37, 2000.
Yu et al., “APRIL and TALL-1 and receptors BCMA and TACI: system for regulating humoral immunity,” Nature Immunology 1(3):252-256, 2000.
Roth et al., “APRIL, a new member of the tumor necrosis factor family, modulates death ligand-induced apoptosis,” Cell Death and Differentiation 8:403-410, 2001.
Von Bulow et al., “Regulation of the T-Independent Humoral Response by TACI,” Immunity 14:573-582, 2001.
Xu et al., “B-Cell Maturation Protein, Which Binds the Tumor Necrosis Factor Family Members BAFF and APRIL, Is Dispensable for Humoral Immune Responses,” Molecular and Cellular Biology 21(12):4067-4074, 2001.
Khare et al., “The role of TALL-1 and APRIL in immune regulation,” TRENDS In Immunology 22(2):61-63, 2001.
Laabi et al., “Lymphocyte Survival—Ignorance is BLys,” Science 289(5481):883, 2000.
Shu et al., “TALL-1 is a novel member of the TNF family that is down-regulated by mitogens,” Journal of Leukocyte Biology 65:680-683, 1999.
Lopez-Fraga et al., “Biologically active APRIL is secreted following intracellular processing in the Golgi apparatus by furin convertase,” EMBO Reports 2(10):945-951, 2001.
Roschke et al., “BLyS and APRIL Form Biologically Active Heterotrimers That Are Expressed in Patients with Systemic Immune-Based Rheumatic Diseases,” Journal of Immunology 169:4314-4321, 2002.
Pradet-Balade et al., “An endogenous hybrid mRNA encodes TWE-PRIL, a functional cell surface TWEAK-APRIL fusion protein,” EMBO Journal, 21(21):5711-5720, 2002.
Litinskiy et al., “DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL,” Nature Immunology 3(9):822-829, Sep. 2002.
Macpherson et al., “BLySsful interactions between DCs and B cells,” Nature Immunology 3(9):798-800, Sep. 2002.
Golub, E.S. and Green, D.R.,Immunology: a Synthesis, 2ndedition, Sunderland, MA:Sinauer Associates, Inc., pp. 153-154 (1991).
Deng et al., “Basis for selection of improved carbohydrate-binding single-chain antibodies from synthetic gene libraries,”Proc. Natl. Acad. Sci. USA, 92:4992-4996 (May 1995).
Barbas et al., “In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity,”Proc. Natl. Acad. Sci. USA, 91:3809-3813 (Apr. 1994).
Deng et al., “Selection of Antibody Single-chain Variable Fragments with Improved Carbohydrate Binding by Phage Display,”J. Biol. Chem., 269(13):9533-9538 (Apr. 1, 1994).
Schier et al., “Isolation of Picomolar Affinity Anti-c-erbB-2 Single-chain Fv by Molecular Evolution of the Complementarity Determining Regions in the Center of the Antibody Binding Site,”J. Mol. Biol., 263:551-567 (1996).
Seshasyaee et al, “Loss of TACI Causes Fatal Lymphoproliferation and Autoimmunity, Establishing TACI as an Inhibitory BLyS Receptor,”Immunity, 18:279-288 (2003).
Blanchard David J.
Huff Sheel J.
Human Genome Sciences Inc.
Human Genome Sciences Inc.
LandOfFree
Antibodies against tumor necrosis factor delta (APRIL) does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies against tumor necrosis factor delta (APRIL), we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies against tumor necrosis factor delta (APRIL) will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3734646